Research has revealed interaction between NLRP3 and TREM2 signaling, indicating that modulating the NLRP3 inflammasome to maintain TREM2 function could offer therapeutic potential for C9orf72-ALS/FTD [139]. The gene discussed is C9orf72; the disease is frontotemporal dementia.